Rezatapopt shrank tumors in 48% of 65 women with platinum-resistant or refractory ovarian cancer and a TP53 Y220C mutation, but the single-arm trial cannot establish survival benefits.
Rezatapopt Pill Shrank Tumors in 48% of Women With Platinum-Resistant Ovarian Cancer
by | Nov 21, 2026 | Uncategorized | 0 comments

Recent Comments